Kornimate/medical-research-clean huggingface dataset:
timing of umbilical cord occlusion in premature babies( <33 w). delayed vs early.

Conditions: Delayed Umbilical Cord Clamping Benefits; Postpartum Haemorrhage; Intraventricular Haemorrhage

Summary: early cord clamping after delivery has been common practice for many decades as part of the active management of the third stage of labour. however in recent years, several studies have shown that delayed cord clamping may offer important benefits to the newborn. the data gathered indicate that delayed cord clamping may be particularly useful in premature babies, between 26 and 32 weeks of gestational age, reducing the need for blood transfusion and the incidence of intraventricular haemorrhage. however it is argued that the described potential benefits of delayed cord clamping could be negated by the increased risk of polycythaemia and jaundice in the newborn, as well as by potential interference with the postpartum haemorrhage management, initial care and reanimation of the premature newborn, and the possibility of cord blood donation. these factors, together with as the lack of homogeneity among existing studies regarding the delayed cord clamping technique create the need, in our opinion, for further research, to establish the proper place of this measure. our hypothesis is that delayed cord clamping in the premature newborn significatively reduces the need for blood transfusions and intraventricular haemorrhage, compared with usual early cord clamping. secondary outcomes: * to define the impact of delayed cord clamping on neonatal assessment parameters after delivery: apgar score, cord ph, need for mechanical ventilation or reanimation. * neonatal mortality and morbidity * effect of the procedure on the incidence and severity of maternal postpartum haemorrhage * to study the correlation between iron metabolism and reticulocitary haemoglobin levels in cord and infant blood.


Eligibility criteria:
inclusion criteria: * deliveries ( either vaginal or by c-section) between 26 and 32.6 weeks of gestation. * patients must be over 18 years old. * patient understands and signs informed consent. exclusion criteria: * urgent c-section * gestational age under 22 or over 33 weeks * major fetal anomalies (requiring surgery or with a high risk of neonatal death or incapacity) * major uterine malformations * placenta previa. * multiple gestations * fetal hydrops * severe iso- immunization * hiv-positive mother * severe intrauterine growth restriction ( reverse atrial flow in dv) * intrauterus ventricular haemorrhage
a new surgery platform for calcaneal surgery: a clinical research

Conditions: Calcaneus Fracture

Summary: purpose: study on the method of lateral nursing and surgical operating tables optimization in the calcaneal surgery. method:design combined surgical operating tables grouped according to the time of clinical application.58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. the traditional lateral method and calcaneus lateral surgery platforms are separately applied to compare the sliding of the affected limb during a surgery, the stability of the position, the difference of the surgical instruments fall and the satisfaction of the medical staff.moreover,30 healthy volunteers are selected to experience the comfort level of the two placement methods.


Eligibility criteria:
inclusion criteria: * ages ranged from 18 to 82. * asa ⅰ or ⅱ level. exclusion criteria: * limited body activity and extremely severe cardiovascular diseases. * unwilling to cooperate. * mental illness and coagulopathy
ehealth intervention to manage depression and anxiety in patients with ischemic heart disease

Conditions: Depression, Anxiety

Summary: this study evaluates the effectiveness and cost-effectiveness of a therapy-assisted internet-based intervention in patients with ischemic heart disease and co-morbid depression and anxiety referred for cardiac rehabilitation. half of the patients will receive the intervention and the other half usual care. we hypothesize that the intervention will lead to a reduction in patients' symptoms of depression and anxiety and be cost-effective.

the 12-week intervention will consist of 9 modules and 2 optional modules that will be delivered to patients in the active intervention via a platform or app. psychologists will provide asynchronous guidance via the platform. motivational interviewing will be used during the intervention to prevent dropout. the psychologist may contact patients via telephone during the intervention if needed. all patients will have access to the intervention up to 6 months' post intervention so that they can revisit the material and reuse it on a need-to-basis. patients will be recommended to use this option and to note specific time points in their agenda where they will access the intervention. a brief purpose-designed interview protocol that includes elements from the scan interview will be carried out by psychologists trained in conducting the interview.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * diagnosis of ischemic heart disease (diagnostic codes i20-i25) * referred for cr * hads score ≥ 8 on depression and or anxiety * access to a computer or smart phone * ability to use computer or smart phone * proficient in the danish language * signing an informed consent form exclusion criteria: * severe psychiatric disorder (i.e., borderline disorder, schizophrenia or bipolar disorder) * severe cognitive difficulties (e.g. severe brain damage, mental retardation, or dementia) that will prevent patients from participating * endorsement of suicidal ideation with daily suicidal thoughts (phq-9 item 9 \>2) * participation in other intervention studies (unless they are clinical studies) * seeing a psychologist or mental health professional for the treatment of anxiety and depression
the therapeutic effects of topical cannabidiol (cbd) products for atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the goal of this observational study is to learn about the potential therapeutic effects of topical cbd products produced by phoilex ltd., specifically the releaf gel, in those diagnosed with atopic dermatitis. patients will be routinely assessed via questionnaire, and physical measurements will be taken with respect to the affected area studied in order to judge clinical efficacy. the main question\[s\] it aims to answer are: * did you experience an immediate increase in skin hydration? * did you experience a soothing or comforting feeling on your irritated skin area? please explain where your affected area is located, and also include at what time point this occurred. example: affected area: palm, time point: 1-hour post-application * upon the affected area being in the healing phase, was your skin itch/scratch free for 4/6/10/12 hours (please circle)? * did you experience immediate relief from your skin inflammation? * did the study cream absorb quickly into your skin, without any greasy feeling? * has your skin flare disappeared in 2 week(s)? * has your skin condition appearance improved? (yes/no) participants will apply phoilex releaf gel (a cream) to their affected areas of atopic dermatitis. the questions listed above shall be discussed and observations recorded at the 0 week, 1 week, 2 week, and 4 week time points. additional monitoring questions may be asked of the participants to ensure the safety of the product. a chart will be provided to the participants to track phoilex releaf gel usage (how many pumps, and time of day) throughout duration of the study. we hypothesize that releaf gel will be suitable to ameliorate the common signs and symptoms of atopic dermatitis as well as improve patient quality of life.


Eligibility criteria:
inclusion criteria: * specifically, patients would be recruited based on the following inclusion criteria must be over 18 years old and must be diagnosed with moderate-to-severe eczema. exclusion criteria: * exclusion criteria would include not currently using any steroids or biologics, not currently using any other topical products, not pregnant, not breast feeding, nor have any allergies to any ingredients listed within the formula of the releaf gel. a negative pregnancy test will need to be confirmed prior to patient receiving phoilex releaf gel. lastly, participants who have been diagnosed with anxiety or depression with a classification of greater than mild anxiety or mild depression will be excluded. as such, screening for possible candidates for the clinical trial will include questions and a brief assessment on participants mental health by study doctor/physician.
immunotherapy adjacent to cervical cancer (ithaca) study

Conditions: Cervical Cancer

Summary: the ithaca study is a phase i study evaluating the safety and toxicity of a peritumorally injected pd-1 checkpoint inhibitor, in combination with a multifunctional ctla-4 inhibitor, in early-stage cervical cancer.

in this single arm, open label phase i study, the investigators will study the safety and toxicity of the combination of a pd-1 checkpoint inhibitor and a multifunctional ctla-4 inhibitor when injected peritumorally prior to surgery in early-stage cervical cancer. additional objectives are to describe dose limiting toxicities, to determine the maximum tolerated doses and to study the effects on the tumor and lymph node microenvironment, and on immune subsets in peripheral blood.

Eligibility criteria:
inclusion criteria: * early-stage cervical cancer * scheduled for (radical) hysterectomy and pelvic lymph node dissection exclusion criteria: * previous treatment with checkpoint inhibitors * use of immunosuppressive medication within 28 days of the injection of the study medication * history of other malignancy

Keywords: immune therapy check point inhibitor peritumoral administration
oral protein supplements for nutritional and quality of life improvement after pancreatic resection in elderly patients

Conditions: Pancreatic Cancer; Cholangiocarcinoma; Intraductal Papillary Mucinous Neoplasm; Neuroendocrine Tumor; Solid Pseudopapillary Tumor

Summary: this study investigates the effects of oral protein supplements on the nutritional status and quality of life in elderly patients following standard pancreatic resection. the research aims to determine whether these supplements can improve protein intake and contribute to better skeletal muscle mass, which is critical for recovery and overall health. the study hypothesizes that higher compliance with protein supplementation will be positively correlated with increased protein intake and improved muscle mass index, potentially leading to enhanced postoperative outcomes in this patient population.

this study was a randomized, double-blind, placebo-controlled clinical trial conducted to assess the effects of oral protein supplements on nutritional status and quality of life in elderly patients following pancreaticobiliary surgery. the study included elderly patients aged 65 years or older who underwent surgery for pancreaticobiliary cancer. the trial was conducted between january 7, 2021, and july 18, 2022. a total of 60 patients were initially enrolled, but after 19 dropouts, the final analysis was based on 41 patients (18 in the placebo group and 23 in the experimental group). the experimental group received protein supplements providing 18g of protein per day, while the control group received a placebo containing carbohydrates instead of protein. key outcomes such as nutrient intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed were measured at three time points: before surgery, at discharge, and during an outpatient visit. the data were analyzed using a linear mixed-effects model to evaluate the effects of the intervention.

Eligibility criteria:
inclusion criteria: * patients aged 65 years or older who were diagnosed with and underwent surgery for one of the following cancers: 1. pancreatic cancer 2. cholangiocarcinoma 3. intraductal papillary mucinous neoplasm 4. neuroendocrine tumor 5. solid pseudopapillary tumor. exclusion criteria: * patients were excluded from the study if they met any of the following criteria: 1. patients who were assessed as severely malnourished before surgery (pg-sga grade c); 2. patients with an estimated glomerular filtration rate (egfr) of less than 60 ml/min, or those diagnosed with chronic kidney disease and a history of related treatment; 3. patients with a body mass index (bmi) of 30 kg/m² or higher; 4. patients with ascites or edema severe enough to affect weight evaluation; 5. patients whose bioelectrical impedance analysis (bia) could not be measured due to the use of pacemakers or implants; 6. patients whom the researcher deemed unable to participate in the study for psychological or cognitive reasons; 7. patients who did not provide consent for participation in this study.
intravenous tedisamil in the rapid conversion of atrial fibrillation or flutter to normal sinus rhythm in female subjects

Conditions: Atrial Fibrillation; Atrial Flutter

Summary: the purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (nsr) in female patients.


Eligibility criteria:
inclusion criteria: * willing to sign informed consent before screening examinations are performed and before the study drug is administered * females \> 18 years of age * subjects with documented (60 second rhythm strip) symptomatic atrial fibrillation or flutter (duration \> 3 hours and \< 45 days) at the time of randomization * subjects who are in no distress and hemodynamically stable (supine systolic blood pressure \> 90 mmhg and diastolic blood pressure \< 105 mmhg) exclusion criteria: * pregnancy and lactation * acute myocardial infarction and cerebrovascular accidents * coronary syndromes and congestive heart failure (chf) new york heart association (nyha) iv * life-threatening ventricular arrhythmias and electrocardiogram (ecg) abnormalities * concurrent antiarrhythmic treatments

Keywords: atrial fibrillation, atrial flutter, anti-arrhythmic agents, conversion to normal sinus rhythm
effect of quadriceps muscle on physical outcome measures in women with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: studies have reported that individuals with rheumatoid arthritis have a smaller muscle cross-sectional area, pennation angle and muscle thickness than healthy controls. sarcopenia may decrease physical performance and quality of life in individuals with ra. therefore, morphologic changes in the quadriceps femoris muscle due to sarcopenia may help us to gain insight into physical function and quality of life. this study aims to evaluate the predictive capacity of morphologic characteristics of the quadriceps femoris muscle for disease activity, physical performance, and quality of life in women with rheumatoid arthritis.

studies have reported that individuals with rheumatoid arthritis have a smaller muscle cross-sectional area, pennation angle and muscle thickness than healthy controls. sarcopenia may decrease physical performance and quality of life in individuals with ra. therefore, morphologic changes in the quadriceps femoris muscle due to sarcopenia may help us to gain insight into physical function and quality of life. this study aims to evaluate the predictive capacity of morphologic characteristics of the quadriceps femoris muscle for disease activity, physical performance, and quality of life in women with rheumatoid arthritis. within the scope of the study, the morphological characteristics of the quadriceps muscle of the participants will be evaluated by a physical medicine and rehabilitation specialist physician via ultrasound. after appropriate visualization, the image will be captured and saved in jpeg format, and will be exported to the imagej program for further analysis and evaluations will be performed by an anatomist. assessments of quality of life and physical performance will be made by a physiotherapist involved in the study.

Eligibility criteria:
inclusion criteria: * 18-60 years old * female participants with a confirmed diagnosis of ra for at least 3 years according to the 2010 american college of rheumatology (acr) criteria * presence of sarcopenia exclusion criteria: * presence of fractures, burns or lesions in the area to be measured * presence of any neuromuscular, cardiovascular or metabolic disease, * individuals with knee endoprosthesis, * inability to walk
comparison between split septum and mechanical valve needleless connector in preterm babies

Conditions: Sepsis, Neonatal

Summary: the goal of this clinical trial study is to compare the effectiveness between split septum and mechanical valve needleless connector in very preterm babies (or under 1500 grams) the main questions it aims to answer are: * what is the incidence of central line-associated bloodstream infections when using a split septum connector? * what is the incidence of central line-associated bloodstream infections when using a mechanical valve connector? * what is the ratio length of stay between babies with birth weight \< 1500 grams who use split septum connector and mechanical valve? * what is the ratio incidence of mortality due to sepsis of babies with birth weight \< 1500 grams who use split septum connector and mechanical valve? participants will be observed for two weeks after insertion of central line. they will be taken blood sample for culture and sepsis marker panel. researchers will compare split septum group and mechanical valve group to see if there is a central line associated bloodstream infections


Eligibility criteria:
inclusion criteria: * preterm neonates with gestational age less than and equal to 32 weeks * birth weight less than 1500 gram * neonates indicated to use central line access * parents are willing to participate in this study and has filled and signed the informed consent letter exclusion criteria: * neonates who are previously diagnosed as clabsi * neonates who has other focus of infection that are diagnosed before the recruitment * suffer from congenital abnormalities
contemporary transvenous lead extraction outcomes

Conditions: Pacemaker Lead Dysfunction; Pacemaker Electrode Infection; ICD; Endocarditis Infective

Summary: presentation of procedural safety and outcomes data from a high volume tle centre

transvenous lead extraction is crucial procedure in the longterm management of patients with implanted pacemakers or cardioverter defibrillators. our study presents the patient and procedural characteristics as well as the outcome data of a cohort undergoing transvenous lead extraction (tle) with olny mechanical extraction tools at a high-volume tle centre.

Eligibility criteria:
inclusion criteria: * all patients undergoing a lead removal procedure exclusion criteria: * minors
iliac, common and external (ice) artery stent trial

Conditions: Vascular Lesions

Summary: the objective of this prospective, randomized,controlled and multicenter trial is, to compare recurrent-restenosis rates in the balloon expandable visio-pro stent arm and the selfexpandable protege gps stent arm 12 month after treatment of stenosis or occlusions of common and external iliac artery disease.


Eligibility criteria:
inclusion criteria: 1. age \> 21 years. 2. patient must sign informed consent form. 3. patient must agree to participate in the study and comply with follow-up requirements. 4. clinically, all patients must be in rutherford category 1 to 4. angiographic inclusion criteria: 5. planned stenting (degree of stenosis 70-100%) within the common or external iliac artery. the target lesion must not extend beyond the iliac arteries. 6. lesion segment starts at the aortic bifurcation and ends at the take off of the common femoral artery (offset of the iliac circumflex artery beneath the ligamentum inguinale). 7. the length of the lesion should be at least 1 cm and maximally 20 cm (measurement by radiopaque ruler). 8. the degree of target lesion stenosis must be determined by pre-interventional duplex ultrasound or (mr-) angiography. 9. patency of ipsilateral profunda artery. ipsi- or contralateral artery lesions of the leg can be treated prior to the treatment of the study lesion. 10. in cases of two or more stenotic regions within the segment, these are considered separate lesions if there is a nonstenotic or only mildly stenotic (\< 30%) segment of at least 2 cm in length between them. otherwise, they are considered as single lesion. in case of separate lesions, only the proximal lesion will be taken as the target lesion! 11. a tandem lesion that can be treated with one stent will be considered as one lesion. exclusion criteria: 1. patient is currently participating in another clinical trial 2. pregnancy or pregnancy planned during study duration 3. life expectancy less than 2 years 4. co-morbidities preventing study participation 5. severe coagulation disorders 6. current treatment with anticoagulants other than aspirin, ticlopidine, clopidogrel or prasugrel. 7. active gastric ulcer or gastrointestinal bleeding 8. thrombotic occlusion of the target vessel within previous 4 weeks. 9. treatment of target lesion with laser or atherectomy devices. 10. dialysis dependency. 11. manifest hyperthyreosis. 12. known allergy against contrast agent that cannot be adequately controlled by usual premedication. 13. known heparin intolerance. 14. known paclitaxel intolerance. angiographic: 15. target lesion extends into the femoral artery. 16. symptomatic untreated inflow lesion \> 70% in ipsilateral iliac arteries. pretreatment of iliac stenosis is possible. 17. target lesion is in aortic bifurcation and needs treatment with "kissing balloon technique" 18. lesion in abdominal aorta that needs treatment.

Keywords: common iliac artery and external iliac artery